Isopsoralen

CAS No. 523-50-2

Isopsoralen( Isopsoralen )

Catalog No. M18721 CAS No. 523-50-2

Angelicin, is a furanocoumarin with anti-Y, antiviral, anti-inflammatory activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 In Stock
5MG 78 In Stock
10MG 122 In Stock
25MG 219 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Isopsoralen
  • Note
    Research use only, not for human use.
  • Brief Description
    Angelicin, is a furanocoumarin with anti-Y, antiviral, anti-inflammatory activity.
  • Description
    Angelicin, is a furanocoumarin with anti-Y, antiviral, anti-inflammatory activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Isopsoralen
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    523-50-2
  • Formula Weight
    186.17
  • Molecular Formula
    C11H6O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 33.33 mg/mL 179.04 mM; H2O : < 0.1 mg/mL
  • SMILES
    c1cc2c(cco2)c2c1ccc(=O)o2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lu H, et al. Afr Health Sci. 2014 Sep;14(3):641-7.
molnova catalog
related products
  • Dihydroxyfumaric aci...

    Dihydroxyfumaric acid is a known generator of superoxide anions and by hydroxyl free radicals. Dihydroxyfumarate exposure can cause insulin inhibitory effects. It can spontaneously convert to hydroxypyruvate or to oxaloglycolate.

  • (+)-Puerol B 2-O-glu...

    (+)-Puerol B 2''-O-glucoside is a natural product for research related to life sciences.

  • lorvotuzumab

    Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.